This monoclonal anti-mutated Calreticulin CALR (CAL2) antibody recognises all forms of C-terminus mutated CALR.
Calreticulin (CALR) mutations
Calreticulin (CALR) mutations have been identified as a major driver in myeloproliferative neoplasms (MPNs). In contrast to JAK2 mutations that are mainly associated with polycythaemia vera (PV), CALR mutations are specifically associated with primary myelofibrosis (PMF) and essential thrombocythaemia (ET). All known types of CALR mutations result in a novel epitope at the C-terminus of the protein.
The anti-mutated calreticulin (CALR) CAL2 antibody
The anti-mutated calreticulin CAL2 antibody HistoSure is offering is directed against this neoepitope, and recognize all forms of C-terminus mutated CALR. It fills a diagnostic gap in ET and PMF patients harboring non-mutated JAK2/MPL and has been successfully used for differentiation between mutated and non-mutated CALR in PMF and ET.